167 related articles for article (PubMed ID: 31205644)
21. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
22. A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies.
Rundgren IM; Ersvær E; Ahmed AB; Ryningen A; Bruserud Ø
Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31963675
[No Abstract] [Full Text] [Related]
23. Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.
Sukswai N; Khoury JD
Curr Hematol Malig Rep; 2019 Oct; 14(5):368-375. PubMed ID: 31338668
[TBL] [Abstract][Full Text] [Related]
24. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.
Guerra VA; Jabbour EJ; Ravandi F; Kantarjian H; Short NJ
Ther Adv Hematol; 2019; 10():2040620719849496. PubMed ID: 31205644
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies in frontline acute lymphoblastic leukemia.
Chew S; Jammal N; Kantarjian H; Jabbour E
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101226. PubMed ID: 33279178
[TBL] [Abstract][Full Text] [Related]
26. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
Uy N; Nadeau M; Stahl M; Zeidan AM
J Blood Med; 2018; 9():67-74. PubMed ID: 29713210
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies in acute lymphoblastic leukemia.
Jabbour E; O'Brien S; Ravandi F; Kantarjian H
Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
[TBL] [Abstract][Full Text] [Related]
28. Antibody based therapy in relapsed acute lymphoblastic leukemia.
Jammal N; Chew S; Jabbour E; Kantarjian H
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
[TBL] [Abstract][Full Text] [Related]
29. Antibody-based therapies in patients with acute lymphoblastic leukemia.
Dinner S; Liedtke M
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):9-15. PubMed ID: 30504286
[TBL] [Abstract][Full Text] [Related]
30. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
31. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.
Short NJ; Jabbour E; Albitar M; de Lima M; Gore L; Jorgensen J; Logan AC; Park J; Ravandi F; Shah B; Radich J; Kantarjian H
Am J Hematol; 2019 Feb; 94(2):257-265. PubMed ID: 30394566
[TBL] [Abstract][Full Text] [Related]
32. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
33. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Runcie K; Budman DR; John V; Seetharamu N
Mol Med; 2018 Sep; 24(1):50. PubMed ID: 30249178
[TBL] [Abstract][Full Text] [Related]
34. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
Al-Salama ZT
Target Oncol; 2018 Aug; 13(4):525-532. PubMed ID: 30090971
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
